Interest in Rh testing and Rh immunoglobulin treatment among patients obtaining telehealth medication abortion
There is low patient interest in Rh testing and Rh immunoglobulin treatment for first-trimester medication abortion through telehealth. There is a need for clinical guidelines to incorporate patient preferences. Guidelines that do not require Rh testing and treatment following first-trimester abortion are consistent with evidence-based patient-centered abortion care.
Authors
- Leah R. Koenig (ORCID: https://orcid.org/0000-0002-4982-8672)
- Jennifer Ko (ORCID: https://orcid.org/0009-0002-9989-1386)
- Ushma D. Upadhyay (ORCID: https://orcid.org/0000-0002-2731-2157)
- Karen Meckstroth
- Linda J Shin (ORCID: https://orcid.org/0009-0002-3206-8707)
Institutions
- University of California System (US)
- Reproductive Science Center (US)
- Global Brain Health Institute (US)
Publication Details
- Journal
- Contraception
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1016/j.contraception.2025.110856
- Primary Topic
- Blood groups and transfusion
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Erik och Edith Fernströms Stiftelse för Medicinsk Forskning
- University of California, San Francisco
- National Institute of Child Health and Human Development
- National Institute on Minority Health and Health Disparities
- Eunice Kennedy Shriver National Institute of Child Health and Human Development